Omar M Rahal1, Adam R Wolfe1, Pijus K Mandal2, Richard Larson1, Sanda Tin3, Cristina Jimenez4, Dadong Zhang5, Janet Horton6, James M Reuben3, John S McMurray2, Wendy A Woodward7. 1. M. D. Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas, USA; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 2. Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 3. M. D. Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas, USA; Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 4. Department of Biology, University of Puerto Rico-Rio Piedras, San Juan, Puerto Rico. 5. Duke Cancer Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA. 6. Duke University Medical Center, Durham, North Carolina, USA; Department of Radiation Oncology, Durham, North Carolina, USA. 7. M. D. Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas, USA; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Electronic address: wwoodward@mdanderson.org.
Abstract
PURPOSE: To determine the role of macrophage polarization on the response of inflammatory breast cancer (IBC) cells to radiation and whether modulation of macrophage plasticity can alter radiation response. METHODS AND MATERIALS: The human THP-1 monocyte cell line and primary human monocytes isolated from peripheral blood mononuclear cells were differentiated into macrophages and polarized to either an "antitumor" (M1) or a "protumor" (M2) phenotype. These polarized macrophages were co-cultured with IBC cells (SUM149, KPL4, MDA-IBC3, or SUM190) without direct contact for 24 hours, then subjected to irradiation (0, 2, 4, or 6 Gy). Interleukin (IL)4/IL13-induced activation of STAT6 signaling was measured by Western blotting of phospho-STAT6 (Tyr641), and expression of M2 polarization gene markers (CD206, fibronectin, and CCL22) was measured by quantitative polymerase chain reaction. RESULTS: Expression of M2 polarization markers was higher in M2-polarized macrophages after IL4/IL13 treatment than in control (M0) or M1-polarized macrophages. Co-culture of IBC cell lines with M1-polarized THP-1 macrophages mediated radiosensitivity of IBC cells, whereas co-culture with M2-polarized macrophages mediated radioresistance. Phosphopeptide mimetic PM37, targeting the SH2 domain of STAT6, prevented and reversed IL4/IL13-mediated STAT6 phosphorylation (Tyr641) and decreased the expression of M2 polarization markers. Pretreatment of M2-THP1 macrophages with PM37 reduced the radioresistance they induced in IBC cells after co-culture. Targeted proteomics analysis of IBC KPL4 cells using a kinase antibody array revealed induction of protein kinase C zeta (PRKCZ) in these cells only after co-culture with M2-THP1 macrophages, which was prevented by PM37 pretreatment. KPL4 cells with stable short hairpin RNA knockdown of PRKCZ exhibited lower radioresistance after M2-THP1 co-culture. CONCLUSIONS: These data suggest that inhibition of M2 polarization of macrophages by PM37 can prevent radioresistance of IBC by down-regulating PRKCZ.
PURPOSE: To determine the role of macrophage polarization on the response of inflammatory breast cancer (IBC) cells to radiation and whether modulation of macrophage plasticity can alter radiation response. METHODS AND MATERIALS: The humanTHP-1 monocyte cell line and primary human monocytes isolated from peripheral blood mononuclear cells were differentiated into macrophages and polarized to either an "antitumor" (M1) or a "protumor" (M2) phenotype. These polarized macrophages were co-cultured with IBC cells (SUM149, KPL4, MDA-IBC3, or SUM190) without direct contact for 24 hours, then subjected to irradiation (0, 2, 4, or 6 Gy). Interleukin (IL)4/IL13-induced activation of STAT6 signaling was measured by Western blotting of phospho-STAT6 (Tyr641), and expression of M2 polarization gene markers (CD206, fibronectin, and CCL22) was measured by quantitative polymerase chain reaction. RESULTS: Expression of M2 polarization markers was higher in M2-polarized macrophages after IL4/IL13 treatment than in control (M0) or M1-polarized macrophages. Co-culture of IBC cell lines with M1-polarized THP-1 macrophages mediated radiosensitivity of IBC cells, whereas co-culture with M2-polarized macrophages mediated radioresistance. Phosphopeptide mimetic PM37, targeting the SH2 domain of STAT6, prevented and reversed IL4/IL13-mediated STAT6 phosphorylation (Tyr641) and decreased the expression of M2 polarization markers. Pretreatment of M2-THP1 macrophages with PM37 reduced the radioresistance they induced in IBC cells after co-culture. Targeted proteomics analysis of IBC KPL4 cells using a kinase antibody array revealed induction of protein kinase C zeta (PRKCZ) in these cells only after co-culture with M2-THP1 macrophages, which was prevented by PM37 pretreatment. KPL4 cells with stable short hairpin RNA knockdown of PRKCZ exhibited lower radioresistance after M2-THP1 co-culture. CONCLUSIONS: These data suggest that inhibition of M2 polarization of macrophages by PM37 can prevent radioresistance of IBC by down-regulating PRKCZ.
Authors: Anna R Michmerhuizen; Andrea M Pesch; Leah Moubadder; Benjamin C Chandler; Kari Wilder-Romans; Meleah Cameron; Eric Olsen; Dafydd G Thomas; Amanda Zhang; Nicole Hirsh; Cassandra L Ritter; Meilan Liu; Shyam Nyati; Lori J Pierce; Reshma Jagsi; Corey Speers Journal: Mol Cancer Ther Date: 2019-08-14 Impact factor: 6.261
Authors: Heather M McGee; Dadi Jiang; David R Soto-Pantoja; Avinoam Nevler; Amato J Giaccia; Wendy A Woodward Journal: Clin Cancer Res Date: 2019-02-05 Impact factor: 12.531
Authors: Max Hardy-Werbin; Pedro Rocha; Oriol Arpi; Álvaro Taus; Lara Nonell; Xavier Durán; Xavier Villanueva; Deborah Joseph-Pietras; Luke Nolan; Sarah Danson; Richard Griffiths; Miguel Lopez-Botet; Ana Rovira; Joan Albanell; Christian Ottensmeier; Edurne Arriola Journal: Oncoimmunology Date: 2019-03-27 Impact factor: 8.110
Authors: N Zhang; Y Gao; Z Zeng; Y Luo; X Jiang; J Zhang; J Li; J Zhang; Y Gong; C Xie Journal: Clin Transl Oncol Date: 2021-03-28 Impact factor: 3.405